RankAlpha logo
Back to Rankings

PFE

PfizerB
NYSE / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
View Chart
Current thesis
The post-earnings bull read is that Pfizer delivered a clean Q1 beat/reaffirmation, showed 7% operational growth excluding COVID products, and is getting visible help from newer and acquired brands, which supports the deterministic positive prior if execution continues.
Posture
Constructive
Lead driver
Sentiment
What changed
3 setup hits (3d) with net bullish as of 2026-09-09.
What can break
COVID product erosion remains large, with Comirnaty down 59% operationally and Paxlovid down 63% operationally in Q1 2026.
Momentum
64
Value
65
Sentiment
61
Setup hits (3d)
3 · Net Bullish
AI TargetsBase $27.75 · Bull $30.50 · Bear $22.00Analysis 2026-05-08; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-09 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-08 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-09-09

Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-09. Definitions

Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Bullish
Target $28.57
Why
Momentum64 · Δ7d +8.6
Value65 · Δ7d 0.0
Sentiment61 · Δ7d +9.0
So what
Strength-led posture (Net Bullish). Favor watchlist adds and disciplined entries.

Confirming evidence

  • • 3 setup hits (3d) with net bullish as of 2026-09-09.
  • • Sentiment remains the lead driver in the composite, 7D delta +9.0.

Contradictions & invalidation

  • • COVID product erosion remains large, with Comirnaty down 59% operationally and Paxlovid down 63% operationally in Q1 2026.
  • • Cost of sales increased as a percent of revenue, and R&D expense rose 12% operationally as Pfizer spends more on oncology and obesity programs.
  • • The bear read is that earnings quality still relies on offsetting steep COVID declines, cost of sales rose materially, R&D is climbing, and even supportive external coverage framed the bigger recovery as a multi-year process rather than an immediate inflection.

Catalyst clock

2026-05-20

Q1 beat and full-year 2026 guidance reaffirmation reset the post-print baseline

Lead driver: Sentiment · See AI snapshot
Momentum
64
9% active weight
Current posture
7d trendImproving
Δ7d
+8.6
Δ21d
-4.7
Value
65
28% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
+7.5
Sentiment
61
62% active weight
Current posture
7d trendImproving
Δ7d
+9.0
Δ21d
-0.5
Why this grade

Composite grade B. Momentum 64.0 / Value 65.1 / Sentiment 61.2

Scenario snapshot

Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-05-08. Scenario method

B+
Bull case
0%
Probability
Target price
$30.50
Analysis reference price unavailable
Analysis 2026-05-08 · RankAlpha Sentiment Codex
Most likely
B
Base case
1%
Probability
Target price
$27.75
Analysis reference price unavailable
Analysis 2026-05-08 · RankAlpha Sentiment Codex
B-
Bear case
0%
Probability
Target price
$22.00
Analysis reference price unavailable
Analysis 2026-05-08 · RankAlpha Sentiment Codex
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$153.15B
Beta
0.43
Shares Out
5.7B
P/E (TTM)
14.7
P/S (TTM)
2.28
P/FCF (TTM)
213.60
Rev YoY
+2.6%
EPS YoY
-108.6%
Gross Margin
+64.8%
Op Margin
+26.6%
Net Debt
$53.82B
Current Ratio
1.27
As of 2026-09-09 • Updated nightlySource: Internal modelMethods & Data